title: Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
abstract: OBJECTIVE
  To assess the effect and safety of lanthanum carbonate (LC) for hypophosphatemia in patients with end-stage renal disease (ESRD).
  
  
  METHODS
  According to the collaborative review group search strategy, we searched MEDLINE (1996 to 2012.12); EBCO (1996 to 2012.12), and CNKI. We searched Chinese journals by hand. We conducted quality assessment and data extraction by two independent investigators. Meta-analysis was conducted by RevMan 5.0. Results were expressed as OR with 95% confidence interval for dichotomous outcomes and WMD with 95% confidence interval for continuous outcomes.
  
  
  RESULTS
  We identified 16 reports which might meet the inclusion criteria for our review. The meta-analysis showed that LC was superior to placebo in treating hypophosphatemia of end-stage renal disease patients (OR = 5.46, 95% CI: 2.37 to 2.61, p < 0.005) and as efficient as conventional therapies (WMD = -0.06, 95% CI: -0.27 to 0.15, p = 0.57). The incidence of all adverse events was similar between LC- and placebo-treated patients (OR = 1.16, 95% CI: 0.79 to 1.68, p = 0.45).
  
  
  CONCLUSIONS
  Lanthanum carbonate is well effective and tolerated in treating hyperphosphatemia of ESRD patients. Lanthanum carbonate is not likely to cause hypercalcemia compared to calcium-based phosphate binders.
authors.affiliation: The 29th Ward, Jinling Hospital , Nanjing, Jiangsu , China .
authors.forename: Hua
authors.initials: H
authors.lastname: Guo
authors.forename: Xiaojuan
authors.initials: X
authors.lastname: Zhang
authors.forename: Shaowen
authors.initials: S
authors.lastname: Tang
authors.forename: Shali
authors.initials: S
authors.lastname: Zhang
mesh_terms: D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000097:blood; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000401:mortality; D007811:Lanthanum / Q000097:blood / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D061205:Vascular Calcification / Q000139:chemically induced
chemical_list: D010281:Parathyroid Hormone; D010710:Phosphates; C119467:lanthanum carbonate; D007811:Lanthanum; D002118:Calcium